Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen

After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen

Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S. pharmaceutical companies

The Independent UK

Alzheimer's disease blood tests: here's what they look for, and what they can tell you about your risk

Despite affecting 55 million people worldwide, Alzheimer’s disease still has no cure. But recent advancements in the field have seen a number of promising drugs that can slow the disease’s progression pass late-stage clinical trials.

The Conversation

Do new Alzheimer's drugs actually help?

Fast-track approval of three risky drugs intends to slow the disease, but evidence they benefit patients is shaky

Salon

From analysis to the latest developments in health,
read the most diverse news in one place.

New Alzheimer's drugs don't deserve the hype – here's why

A prominent childhood memory is of my grandparents living with and then dying from dementia. As is universal with dementia, there was a double blow: watching my grandparents lose their identity and seeing the suffering of those closest to them.

The Conversation

A trial to test a new path for preventing Alzheimer’s

Alzheimer research made a breakthrough last month when Eli Lilly's drug donanemab slowed cognitive decline in 47% of those taking it. It follows two other drugs, lecanemab and aducanumab, that target amyloid protein buildup in the brain. However, these drugs can cause fatal brain bleeding and seizures. Oxidative stress hypothesis…

The Hindu

New dementia drug raises hopes and fears

These dementia treatments are opening uncharted territory. Here's some of what people should know

Salon

Insurers won't cover new Alzheimer's treatment for some customers

Some private insurers are balking at paying for the first drug fully approved to slow mental decline in Alzheimer’s patients

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

More than 250,000 dementia patients in England could miss new treatments

More than a third of Alzheimer’s patients could miss out on certain drugs because they have no recorded diagnosis, NHS figures show

The Guardian - UK

Alzheimer's drug donanemab has been hailed as a 'turning point' for treatment. But what does it mean for people with the disease?

Trial results of a new drug to treat Alzheimer’s disease, donanemab, shows it can slow cognitive decline by 35%. The drug has been hailed as a “turning point” in Alzheimer’s treatment.

The Conversation

Why is this Alzheimer’s breakthrough so important?

Your questions answered on donanemab.

The Independent UK

New drug found to slow Alzheimer’s hailed as turning point

Donanemab has been found to slow down the disease in a clinical trial.

The Independent UK

Everything we know about breakthrough Alzheimer’s drug Donanemab

Alzheimer’s disease is the most common cause of dementia in the UK

The Independent UK

Alzheimer’s: ‘Turning point’ in fight against disease as drug found to slow decline by up to 35%

Experts say ‘we’re entering a new era where Alzheimer’s disease could become treatable’

Evening Standard

‘Turning point’ in the fight against Alzheimer’s as drug found to slow disease

The results of a new trial were labelled as symbolic of ‘a new era where Alzheimer’s disease could become treatable’

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Second Alzheimer's drug in the pipeline promises to slow worsening but with safety concern

New research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening

WEKU

An experimental Alzheimer's drug outperforms one just approved by the FDA

In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.

The Guardian - UK

Experts urge health regulators to approve ‘turning point’ dementia drugs

Exclusive: As results show 35% slowing in cognitive decline, health leaders say swift decisions crucial

The Guardian - UK

What impact will Alzheimer’s drug donanemab have?

While it is not a cure, proof that drugs can alter course of disease is regarded as significant triumph

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

‘Turning point in the fight against Alzheimer’s’ as drug found to slow disease

Donanemab has been found to slow down the disease in a clinical trial.

The Guardian - UK

New dementia drugs: patients to pay privately or face NHS postcode lottery

As advanced remedies emerge, the chief executive of Alzheimer’s Research UK warns sufferers could miss out as the health service struggles to cope

Zenger

FDA Approves Biogen’s Alzheimer’s Drug That Slows Down Cognitive Decline

The FDA fully approved Biogen Inc. but there are other companies with treatments in the pipeline

Daily Mirror

Miracle new Alzheimer's drug which slows cognitive decline of disease to be rolled out

The Food and Drug Administration (FDA) has approved the much awaited drug Leqembi which has been shown to slow the cognitive decline caused by Alzheimer’s, the most common type of dementia

The Independent UK

FDA fully approves new Alzheimer’s drug to slow down disease progression

‘Today’s action is first verification that a drug targeting underlying disease process has shown clinical benefit’

Al Jazeera

US government approves Alzheimer’s drug to slow cognitive decline

Some insurances, including the government-run Medicare, refused to pay for the drug until it received full approval.

Axios

FDA approves Leqembi, first drug to slow Alzheimer’s progression

Eisai and Biogen's Leqembi is the first drug to slow Alzheimer's progression to receive full FDA approval.

1 2 3 4 5

People

Chiquita BrooksLaSure

14 stories

Maria Carrillo

12 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

193 stories

Biogen

188 stories

Alzheimer Research UK

Eli Lilly and Company

56 stories

JAMA

39 stories

the Alzheimer Association

36 stories

Leqembi

18 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.